Healthy

- Healthy male and female subjects;
- Age: 18 to 55 years (inclusive)
- Body mass index (BMI): above/equal 18 and below/equal 30 kg/m²;
- Women of childbearing age must have a negative pregnancy test and must use adequate contraception throughout the study and for 4 weeks afterwards

- Clinically relevant findings in the ECG
- Incompletely cured pre-existing diseases for which it can be assumed that the absorption, distribution, metabolism, elimination and effects of the study drugs will not be normal
- Known hypersensitivity to moxifloxacin, other quinolones or to any of the excipients
- Known severe allergies, non-allergic drug reactions, or multiple drug allergies
- Relevant diseases within the last 4 weeks prior to the first study drug administration
- Febrile illness within 1 week before the first study drug administration
- Patients with a history of tendon disease/disorder related to quinolone treatment.
- Congenital or documented acquired QT prolongation
- Regular use of medicines (with the exception of contraceptives)
- Pregnancy or lactation
- Regular use of therapeutic or recreational drugs
- Smoking more than 25 cigarettes daily
- Regular daily consumption of more than 500 mL of usual beer or the equivalent quantity of approximately 20 g of alcohol in another form
- Suspicion of drug or alcohol abuse
- Special diets preventing the subjects from eating the standard meals during the study
- Regular daily consumption of more than 1 L of xanthin-containing beverages
- Donation of more than 100 mL of blood within 4 weeks before the first study drug administration or of approximately 500 mL in the preceding 3 months